根據最新的財務報表(Form-10K),Burning Rock Biotech Ltd 的總資產為 $820,淨損失為 $-55
BNR 的關鍵財務比率是什麼?
Burning Rock Biotech Ltd 的流動比率為 2.87,淨利潤率為 -10.2,每股銷售為 $4.99。
Burning Rock Biotech Ltd 的收入按細分市場或地理位置如何劃分?
Burning Rock Biotech Ltd 最大收入來源為 In-hospital,在最近的收益報告中收入為 31,193,232。就地區而言,China 是 Burning Rock Biotech Ltd 的主要市場,收入為 70,898,144。
Burning Rock Biotech Ltd 是否盈利?
無,根據最新的財務報表,Burning Rock Biotech Ltd 的淨損失為 $-55
Burning Rock Biotech Ltd 有負債嗎?
是的,Burning Rock Biotech Ltd 的負債為 285
Burning Rock Biotech Ltd 的流通股有多少?
Burning Rock Biotech Ltd 的總流通股為 107.61
關鍵數據
前收市價
$16.3
開盤價
$16.79
當日範圍
$16.2 - $17.05
52週區間
$2.18 - $41.72
交易量
55.9K
平均成交量
29.2K
股息收益率
--
每股盈餘 (TTM)
-1.16
市值
$166.1M
什麼是 BNR?
Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong and currently employs 674 full-time employees. The company went IPO on 2020-06-12. The firm operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.